(secondQuint)Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis in Patients With Wet AMD.

 This is a phase I, randomized, double-blind, two-group parallel, positive-controlled clinical trial at four centers.

 The primary objective is to assess the initial clinical safety of intravitreal injection of QL1205 or Lucentis(R) in patients with wet age-related macular degeneration (wet-AMD).

 The secondary objective are to assess the initial clinical effectiveness and pharmacokinetic characteristics of intravitreal injection of QL1205 or Lucentis(R) in patients with wet age-related macular degeneration (wet-AMD).

 Subjects would sequentially enrolled according to the protocol in one of two cohorts.

Subjects would receive a single 0.

5mg of QL1205 or Lucentis(R) once a month for three months through vitreous injection.

.

 Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis in Patients With Wet AMD@highlight

This is a randomized, double-blind, two-group parallel, positive-controlled clinical Phase I trial comparing the safety, pharmacokinetics and pharmacodynamics of QL1205 and Lucentis(R) in patients with wet age-related macular degeneration.

